ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,281, issued on Nov. 18, was assigned to Amgen Inc. (Thousand Oaks, Calif.).
"Synthesis of KRAS G12C inhibitor compound" was invented by Michael Thomas Corbett (Agoura Hills, Calif.) and Sebastien Caille (Moorpark, Calif.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers."
The patent was filed on Nov. 13, 2020, under Application No. 17/776,950.
*For further information, including images, charts ...